Darunavir / Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 800 mg/150 mg
Reference Brands: Prezcobix (USA/EU)
Category:
Anti Viral
Darunavir / Cobicistat is available in Tablets
and strengths such as 800 mg/150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Darunavir / Cobicistat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Darunavir / Cobicistat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Darunavir/cobicistat is a fixed-dose combination antiretroviral medication used for the treatment and prevention of HIV-1 infection. It is marketed under the brand name Prezcobix in the USA and Rezolsta in the EU. This combination contains darunavir, an HIV protease inhibitor that blocks viral replication, and cobicistat, a pharmacokinetic enhancer that increases the effectiveness of darunavir by inhibiting its metabolism through the CYP3A enzyme.
Darunavir/cobicistat 800 mg/150 mg tablets are indicated for use in both treatment-naive and treatment-experienced adult patients who do not have darunavir resistance-associated mutations. When administered as part of combination antiretroviral therapy, it helps to suppress viral load, maintain immune function, and reduce the risk of HIV-related complications.
The fixed-dose combination provides convenient once-daily dosing, improving adherence to therapy. Its efficacy in combination with other antiretrovirals has been well documented, making it a cornerstone option in modern HIV management. The combination is available as oral tablets in strengths suitable for both initial and ongoing therapy, offering patients a safe and effective treatment option with proven clinical benefits.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing